Jemal A, Siegel R, Xu J, Ward E. Most cancers statistics, 2010. CA Most cancers J Clin. 2010;60:277–300.
Siegel RL, Miller KD, Wagle NS, Jemal A. Most cancers statistics, 2023. CA Most cancers J Clin. 2023;73:17–48.
Helgstrand JT, Røder MA, Klemann N, Toft BG, Lichtensztajn DY, Brooks JD, et al. Traits in incidence and 5-year mortality in males with newly identified, metastatic prostate most cancers—A population-based evaluation of two nationwide cohorts. Most cancers. 2018;124:2931–8.
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus steady androgen deprivation in prostate most cancers. N. Engl J Med. 2013;368:1314–25.
Fizazi Ok, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in sufferers with newly identified high-risk metastatic castration-sensitive prostate most cancers (LATITUDE): closing total survival evaluation of a randomised, double-blind, section 3 trial. Lancet Oncol. 2019;20:686–700.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus customary antiandrogen remedy for metastatic hormone-sensitive prostate most cancers (ENZAMET): a world, open-label, randomised, section 3 trial. Lancet Oncol. 2023;24:323–34.
Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, et al. Cardiovascular danger in males with prostate most cancers: insights from the RADICAL PC research. J Urol. 2020;203:1109–16.
Hahn AW, Thoman W, Koutroumpakis E, Abdulla A, Subudhi SK, Aparicio A, et al. Cardiometabolic healthcare for males with prostate most cancers: an MD Anderson Most cancers Heart expertise. Cardiooncology. 2023;9:33.
Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naïve males with prostate carcinoma. Most cancers. 2001;91:2238–45.
Pinthus JH, Duivenvoorden WCM, Klotz L, Mukherjee SD, Siemens DR, Niazi T, et al. Low serum testosterone in males with newly identified androgen-deprivation therapy-naïve prostate most cancers and its relationship to cardiovascular danger elements: a RADICAL-PC substudy. J Urol. 2022;207:1020–8.
Harshman LC, Werner L, Tripathi A, Wang X, Maughan BL, Antonarakis ES, et al. The affect of statin use on the efficacy of abiraterone acetate in sufferers with castration-resistant prostate most cancers. Prostate. 2017;77:1303–11.
Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, et al. Metformin in chemotherapy-naive castration-resistant prostate most cancers: a multicenter section 2 trial (SAKK 08/09). Eur Urol. 2014;66:468–74.
Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Adjustments in physique composition throughout androgen deprivation remedy for prostate most cancers. J Clin Endocrinol Metab. 2002;87:599–603.
Chavarro JE, Toth TL, Wright DL, Meeker JD, Hauser R. Physique mass index in relation to semen high quality, sperm DNA integrity, and serum reproductive hormone ranges amongst males attending an infertility clinic. Fertil Steril. 2010;93:2222–31.
Nielsen TL, Hagen C, Wraae Ok, Brixen Ok, Petersen PH, Haug E, et al. Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, intercourse hormone-binding globulin, and luteinizing hormone in younger males. J Clin Endocrinol Metab. 2007;92:2696–705.
Kim C, Dabelea D, Kalyani RR, Christophi CA, Bray GA, Pi-Sunyer X, et al. Adjustments in visceral adiposity, subcutaneous adiposity, and intercourse hormones within the diabetes prevention program. J Clin Endocrinol Metab. 2017;102:3381–9.
Goodpaster BH, Krishnaswami S, Resnick H, Kelley DE, Haggerty C, Harris TB, et al. Affiliation between regional adipose tissue distribution and each kind 2 diabetes and impaired glucose tolerance in aged women and men. Diabetes Care. 2003;26:372–9.
Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al. Potential research of adiposity and weight change in relation to prostate most cancers incidence and mortality. Most cancers. 2007;109:675–84.
Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, et al. Physique mass index, weight change, and danger of prostate most cancers within the Most cancers Prevention Research II Diet Cohort. Most cancers Epidemiol Biomark Prev. 2007;16:63–9.
Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Danger elements for prostate most cancers incidence and development within the well being professionals follow-up research. Int J Most cancers. 2007;121:1571–8.
Amling CL, Riffenburgh RH, Solar L, Moul JW, Lance RS, Kusuda L, et al. Pathologic variables and recurrence charges as associated to weight problems and race in males with prostate most cancers present process radical prostatectomy. J Clin Oncol. 2004;22:439–45.
Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, et al. Prediagnostic body-mass index, plasma C-peptide focus, and prostate cancer-specific mortality in males with prostate most cancers: a long-term survival evaluation. Lancet Oncol. 2008;9:1039–47.
Antoun S, Bayar A, Ileana E, Laplanche A, Fizazi Ok, di Palma M, et al. Excessive subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate most cancers sufferers in publish chemotherapy setting. Eur J Most cancers. 2015;51:2570–7.
Aparicio, Tidwell RSS AM, Yadav SS, Chen JS, Zhang M, Liu J, et al. A modular trial of androgen signaling inhibitor mixtures testing a risk-adapted technique in sufferers with metastatic castration-resistant prostate most cancers. Clin Most cancers Res. 2024;30:2751–63.
Viscuse PV, Tidwell R, Liu J, Guo S, Vundavilli H, Zhang M, et al. DynAMo: A dynamic allocation modular sequential trial of permitted and promising therapies in males with metastatic CRPC. J Clin Oncol. 2022;40:5059.
Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Most cancers cachexia within the age of weight problems: skeletal muscle depletion is a robust prognostic issue, impartial of physique mass index. J Clin Oncol. 2013;31:1539–47.
Revelle W. psych: procedures for psychological, psychometric, and character analysis. 2023.
Wei T, Simko V R. bundle ‘corrplot’: Visualization of a Correlation Matrix (Model 0.92). 2021.
Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue ranges in recurrent prostate most cancers. Clin Most cancers Res. 2005;11:4653–7.
Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet. J 2011;17:10–12.
DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping utilizing next-generation DNA sequencing information. Nat Genet. 2011;43:491–8.
Li H, Durbin R. Quick and correct quick learn alignment with Burrows-Wheeler rework. Bioinformatics. 2009;25:1754–60.
Chen WS, Feng EL, Aggarwal R, Foye A, Beer TM, Alumkal JJ, et al. Germline polymorphisms related to impaired survival outcomes and somatic tumor alterations in superior prostate most cancers. Prostate Most cancers Prostatic Dis. 2020;23:316–23.
Philp LK, Rockstroh A, Sadowski MC, Taherian Fard A, Lehman M, Tevz G, et al. Leptin antagonism inhibits prostate most cancers xenograft development and development. Endocr Relat Most cancers. 2021;28:353–75.
Philp LK, Rockstroh A, Lehman M, Sadowski MC, Bartonicek N, Wade JD, et al. Adiponectin receptor activation inhibits prostate most cancers xenograft development. Endocr Relat Most cancers. 2020;27:711–29.
Hahn AW, Venkatesh N, Msaouel P, McQuade JL. The affect of weight problems on outcomes with immune checkpoint blockade: scientific proof and potential organic mechanisms. Cells. 2023;12:2551.
Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Solar T, et al. SLCO2B1 and SLCO1B3 might decide time to development for sufferers receiving androgen deprivation remedy for prostate most cancers. J Clin Oncol. 2011;29:2565–73.
Hamada A, Sissung T, Value DK, Danesi R, Chau CH, Sharifi N, et al. Impact of SLCO1B3 haplotype on testosterone transport and scientific final result in caucasian sufferers with androgen-independent prostatic most cancers. Clin Most cancers Res. 2008;14:3312–8.
Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, et al. HSD3B1 and resistance to androgen-deprivation remedy in prostate most cancers: a retrospective, multicohort research. Lancet Oncol. 2016;17:1435–44.
Agarwal N, Hahn AW, Gill DM, Farnham JM, Poole AI, Cannon-Albright L. Unbiased validation of impact of HSD3B1 genotype on response to androgen-deprivation remedy in prostate most cancers. JAMA Oncol. 2017;3:856–7.
Khalaf DJ, Aragón IM, Annala M, Lozano R, Taavitsainen S, Lorente D, et al. HSD3B1 (1245A>C) germline variant and scientific outcomes in metastatic castration-resistant prostate most cancers sufferers handled with abiraterone and enzalutamide: outcomes from two potential research. Ann Oncol 2020;31:1186–97.
Lu C, Terbuch A, Dolling D, Yu J, Wang H, Chen Y, et al. Remedy with abiraterone and enzalutamide doesn’t overcome poor final result from metastatic castration-resistant prostate most cancers in males with the germline homozygous HSD3B1 c.1245C genotype. Ann Oncol. 2020;31:1178–85.
O’Reilly MW, Home PJ, Tomlinson JW. Understanding androgen motion in adipose tissue. J Steroid Biochem Mol Biol. 2014;143:277–84.
Hahn AW, Siddiqui BA, Leo J, Dondossola E, Basham KJ, Miranti CK. et al. Most cancers cell-extrinsic roles for the androgen receptor in prostate most cancers.Endocrinology. 2023;164:bqad078
Logothetis CJ, Hahn AW. Difficult the prevailing therapeutic dogma for prostate most cancers: the case for an overlap syndrome. Eur Urol. 2023;85:3–7.
Xu MC, Huelster HL, Hatcher JB, Avulova S, Shares BT, Glaser ZA, et al. Weight problems is related to longer survival impartial of sarcopenia and myosteatosis in metastatic and/or castrate-resistant prostate most cancers. J Urol. 2021;205:800–5.
Lee JS, Lee HS, Ha JS, Han KS, Rha KH, Hong SJ, et al. Subcutaneous fats distribution is a prognostic biomarker for males with castration resistant prostate most cancers. J Urol. 2018;200:114–20.
Govindan S, Cheranda N, Riekhof F, Luo S, Schoen MW. Impact of BMI and hemoglobin A1c on survival of veterans with metastatic castration-resistant prostate most cancers handled with abiraterone or enzalutamide. Prostate. 2023;84:245–53.
Lee CH, Woo YC, Wang Y, Yeung CY, Xu A, Lam KS. Weight problems, adipokines and most cancers: an replace. Clin Endocrinol. 2015;83:147–56.
